Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors
Risks
Default risk
Data is available to registered users only
Volatility
Data is available to registered users only
Selling difficulty
Data is available to registered users only
Stress test
Data is available to registered users only
Country risks
Data is available to registered users only
Other risks
Data is available to registered users only
Sign up to access detailed risk analysis
About
Hemostemix Inc. is a biotechnology firm specializing in the creation, production, and distribution of treatments derived from blood stem cells to address various health issues. These innovative cell therapies are uniquely sourced from a patient's own blood, offering a minimally invasive method to obtain therapeutic cells. The company's primary therapeutic candidate is ACP-01. This autologous (patient's own cells) treatment is currently undergoing Phase II clinical trials in both Canada and the United States. Its primary focus is the treatment of critical limb ischemia, but it is also being evaluated for heart and peripheral arterial diseases. Beyond ACP-01, Hemostemix is actively researching and advancing other distinct cell product lines, including synergistic cell populations and precursors for neural cells. Its corporate headquarters are situated in Calgary, Canada.